Skip to main content
. 2025 Feb 7;31(5):102249. doi: 10.3748/wjg.v31.i5.102249

Table 5.

Comparison of features between the training and validation sets, n (%)

Characteristic
Test (n = 90)
Train (n = 210)
χ 2
P value
Age, years 1.94 0.164
< 60 46 (51.11) 89 (42.38)
≥ 60 44 (48.89) 121 (57.62)
Sex 0.43 0.512
Female 43 (47.78) 109 (51.90)
Male 47 (52.22) 101 (48.10)
BMI, kg/m2 0.21 0.646
< 25 69 (76.67) 166 (79.05)
≥ 25 21 (23.33) 44 (20.95)
TyG 0.31 0.578
Low 47 (52.22) 117 (55.71)
High 43 (47.78) 93 (44.29)
Drinking history 0.24 0.627
No 63 (70.00) 141 (67.14)
Yes 27 (30.00) 69 (32.86)
Smoking history 1.58 0.209
No 67 (74.44) 141 (67.14)
Yes 23 (25.56) 69 (32.86)
ECOG 0.41 0.523
0 57 (63.33) 141 (67.14)
1 33 (36.67) 69 (32.86)
Site 0.08 0.772
Stomach 44 (48.89) 106 (50.72)
Gastric and esophageal binding 46 (51.11) 103 (49.28)
Histological 1.39 0.239
Adenocarcinoma 21 (23.33) 63 (30.00)
Other 69 (76.67) 147 (70.00)
CEA, ng/mL 3.70 0.054
< 3 34 (37.78) 56 (26.67)
≥ 3 56 (62.22) 154 (73.33)
AFP, ng/mL 1.83 0.176
< 15 72 (80.00) 181 (86.19)
≥ 15 18 (20.00) 29 (13.81)
CA-199, ng/mL 1.54 0.214
< 37 60 (66.67) 124 (59.05)
≥ 37 30 (33.33) 86 (40.95)
Liver metastasis 1.60 0.206
No 63 (70.00) 131 (62.38)
Yes 27 (30.00) 79 (37.62)
Peritoneal metastasis 0.73 0.392
No 75 (83.33) 166 (62.38)
Yes 15 (16.67) 79 (37.62)
EBV status 0.10 0.578
No-infect 75 (83.33) 178 (84.76)
Infect 15 (16.67) 32 (15.24)
PD-L1 expression 0.60 0.440
CPS < 5 13 (14.44) 38 (18.10)
CPS ≥ 5 77 (85.56) 172 (81.90)
MMR status 0.02 0.893
pMMR 4 (4.44) 7 (3.33)
dMMR 86 (95.56) 203 (96.67)

BMI: Body mass index; TyG: Triglyceride glucose; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; AFP: Alpha-fetoprotein: CA-199: Carbohydrate antigen 199; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.